Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp Substrate.

Monk SA, Kugler AR, Andersen SW, Ayan-Oshodi MA, James DE, Mullen J, Zimmer JA, Willis BA.

J Clin Pharmacol. 2019 Dec 18. doi: 10.1002/jcph.1558. [Epub ahead of print]

PMID:
31853995
2.

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.

Ye N, Monk SA, Daga P, Bender DM, Rosen LB, Mullen J, Minkwitz MC, Kugler AR.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):233-243. doi: 10.1002/cpdd.422. Epub 2018 Jan 10.

3.

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides.

Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC, Eketjäll S, Kugler AR.

J Clin Pharmacol. 2017 Nov;57(11):1460-1471. doi: 10.1002/jcph.950. Epub 2017 Jun 15.

PMID:
28618005
4.

Simultaneous quantitation of the BACE1 inhibitor AZD3293 and its metabolite AZ13569724 in human matrices by LC-MS/MS.

Li Y, Severin PH, Hoffmann MR, Miller DL, Monk SA, Kugler AR.

Bioanalysis. 2017 May;9(10):813-826. doi: 10.4155/bio-2017-0003. Epub 2017 Apr 24.

5.

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053.

PMID:
27767991
6.

Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol.

Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):442-8. doi: 10.1002/cpdd.204. Epub 2015 Sep 4.

PMID:
27137716
7.

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.

Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M.

Clin Pharmacol Drug Dev. 2015 Nov;4(6):434-41. doi: 10.1002/cpdd.206. Epub 2015 Sep 4.

PMID:
27137715
8.

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.

Eketjäll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G.

J Alzheimers Dis. 2016;50(4):1109-23. doi: 10.3233/JAD-150834.

9.

Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.

Cebers G, Lejeune T, Attalla B, Soderberg M, Alexander RC, Budd Haeberlein S, Kugler AR, Ingersoll EW, Platz S, Scott CW.

J Prev Alzheimers Dis. 2016;3(4):202-218. doi: 10.14283/jpad.2016.119.

PMID:
29199322
10.

Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.

Kaindlstorfer C, Sommer P, Georgievska B, Mather RJ, Kugler AR, Poewe W, Wenning GK, Stefanova N.

Neurotox Res. 2015 Oct;28(3):185-94. doi: 10.1007/s12640-015-9547-7. Epub 2015 Jul 21.

11.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, Farde L.

Brain. 2015 Sep;138(Pt 9):2687-700. doi: 10.1093/brain/awv184. Epub 2015 Jul 1.

PMID:
26137956
12.

Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.

Kirkpatrick WR, Najvar LK, Vallor AC, Wiederhold NP, Bocanegra R, Pfeiffer J, Perkins K, Kugler AR, Sweeney TD, Patterson TF.

J Antimicrob Chemother. 2012 Apr;67(4):970-6. doi: 10.1093/jac/dkr567. Epub 2012 Jan 11.

PMID:
22240402
13.

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.

Beydoun A, Uthman BM, Kugler AR, Greiner MJ, Knapp LE, Garofalo EA; Pregabalin 1008-009 Study Group.

Neurology. 2005 Feb 8;64(3):475-80.

PMID:
15699378
14.

Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.

Arroyo S, Anhut H, Kugler AR, Lee CM, Knapp LE, Garofalo EA, Messmer S; Pregabalin 1008-011 International Study Group.

Epilepsia. 2004 Jan;45(1):20-7.

15.

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures.

French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA.

Neurology. 2003 May 27;60(10):1631-7.

PMID:
12771254
16.

Effects of organic anion, organic cation, and dipeptide transport inhibitors on cefdinir in the isolated perfused rat kidney.

Lepsy CS, Guttendorf RJ, Kugler AR, Smith DE.

Antimicrob Agents Chemother. 2003 Feb;47(2):689-96.

17.

Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease.

Aweeka FT, Gottwald MD, Gambertoglio JG, Wright TL, Boyer TD, Pollock AS, Eldon MA, Kugler AR, Alldredge BK.

Epilepsia. 1999 Jun;40(6):777-82.

18.

Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.

Knapp LE, Kugler AR.

J Child Neurol. 1998 Oct;13 Suppl 1:S15-8; discussion S30-2. Review.

PMID:
9796747
19.

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.

Kugler AR, Annesley TM, Nordblom GD, Koup JR, Olson SC.

Clin Chem. 1998 Jul;44(7):1474-80.

20.
21.

Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.

Wilder BJ, Campbell K, Ramsay RE, Garnett WR, Pellock JM, Henkin SA, Kugler AR.

Arch Neurol. 1996 Aug;53(8):764-8.

PMID:
8759983
22.

The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.

Boucher BA, Feler CA, Dean JC, Michie DD, Tipton BK, Smith KR Jr, Kramer RE, Young B, Parks BR Jr, Kugler AR.

Pharmacotherapy. 1996 Jul-Aug;16(4):638-45.

PMID:
8840370
23.

Pharmacology and pharmacokinetics of fosphenytoin.

Browne TR, Kugler AR, Eldon MA.

Neurology. 1996 Jun;46(6 Suppl 1):S3-7. Review.

PMID:
8649612
24.

Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: in vivo micropuncture studies.

Smith DE, Kugler AR, Schnermann JB.

J Pharm Sci. 1995 Oct;84(10):1147-50.

PMID:
8801325
25.

Disposition of quinapril and quinaprilat in the isolated perfused rat kidney.

Kugler AR, Olson SC, Smith DE.

J Pharmacokinet Biopharm. 1995 Jun;23(3):287-305.

27.

Influence of intrarenal metabolism on the analysis of renal drug transport mechanisms.

Smith DE, Kugler AR.

J Pharm Sci. 1994 Oct;83(10):1519-20. No abstract available.

PMID:
7884678

Supplemental Content

Loading ...
Support Center